Circulating Endothelial Cells and Procoagulant Microparticles in Patients with Glioblastoma: Prognostic Value

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Reynés, Gaspar ^a   Vila, Virtudes ^a   Fleitas, Tania ^b   Reganon, Edelmiro ^a   Font de Mora, Jaime ^c   Jordá, María ^a   Martínez Sales, Vicenta ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHOLIPID; TEMOZOLOMIDE; THROMBIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CANCER PROGNOSIS; CELL COUNT; CIRCULATING ENDOTHELIAL CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MEMBRANE MICROPARTICLE; MGMT GENE; OVERALL SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY;

EID: 84880788519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069034     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
3. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ, (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9: 453-461.
4. Kargiotis O, Rao JS, Kyritsis AP, (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78: 281-293.
5. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, et al. (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 2712-2718.
6. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, et al. (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148.
7. Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, et al. (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16: 33-39.
8. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468: 824-828.
9. Erdbruegger U, Dhaygude A, Haubitz M, Woywodt A, (2010) Circulating endothelial cells: markers and mediators of vascular damage. Curr Stem Cell Res Ther 5: 294-302.
10. Boos CJ, Lip GY, Blann AD, (2006) Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 48: 1538-1547.
11. Martínez-Sales V, Sánchez-Lázaro I, Vila V, Almenar L, Contreras MT, et al. (2011) Circulating endothelial cells in patients with heart failure and left ventricular dysfunction. Disease Markers 31: 75-82.
12. Attia FM, Maaty A, Kalil FA, (2011) Circulating endothelial cells as a marker of vascular dysfunction in patients with systemic lupus erythematosus by real-time polymerase chain reaction. Arch Pathol Lab Med 135: 1482-1485.
13. Muntunga M, Fulton B, Bullock R, Batchelor A, Gascoigne A, et al. (2001) Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 163: 195-200.
14. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, et al. (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97: 3658-3661.
15. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, et al. (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15: 139-145.
16. Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, et al. (2012) Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One 7: e47365 Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471832/.
17. Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, et al. (2009) Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 4: 208-213.
18. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, et al. (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108: 452-459.
19. Calleri A, Bono A, (2009) Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res 15: 7652-7657.
20. Mancuso P, Calleri A, Bertolini F, (2012) Circulating endothelial cells and circulating endothelial progenitors. Recent Results Cancer Res 195: 163-170.
21. Batchelor TT, Sorensen AG, Di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95.
22. Morel O, Toti F, Hugel B, Freyssinet JM, (2004) Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 11: 156-164.
23. Cocucci E, Racchetti G, Meldolesi J, (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19: 43-51.
24. Owens AP 3rd, Mackman N (2011) Microparticles in hemostasis and thrombosis. Circ Res 108: 1284-1297.
25. Thaler J, Ay C, Weinstabl H, Dunkler D, Simanek R, et al. (2011) Circulating procoagulant microparticles in cancer patients. Ann Hematol 90: 447-453.
26. Helley D, Banu E, Bouziane A, Banu A, Scotte F, et al. (2009) Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 56: 479-484.
27. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, et al. (2006) Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 4: 671-677.
28. Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, et al. (2010) Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 8: 2571-2574.
29. Manzoni M, Mariucci S, Delfanti S, Rovati B, Ronzoni M, et al. (2012) Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol 138: 1187-1196.
30. Browder T, Butterfield CE, Kraaling BM, Marshall B, O'Reilly MS, et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886.
31. Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, et al. (2009) Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 12: 69-79.
32. Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, et al. (2010) Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 10: 695.
33. Malka D, Boige V, Jacques N, Vimond N, Adenis A, et al. (2012) Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol 23: 919-927.
34. Shao H, Chung J, Balaj L, Charest A, Bigner DD, et al. (2012) Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 18: 1835-1840.
35. Sartori MT, Della Puppa A, Ballin A, Saggiorato G, Bernardi D, et al. (2011) Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 104: 225-231.